Members only

This is a member's only video, please login to watch

Watch Now

To watch this video for free, become a member today!

Join Us

Back to Video List

Error in oncology reporting 02 Nov 2017

Error is inevitable when reporting medical imaging. Furthermore, in oncology, it is often “found out”, as cancers tend to grow. The science of error, and solutions to combat it, are wide and complex. From our local experience of teaching oncology imaging and reviewing discrepancies as part of clinical governance, we have identified a few tips to try and avoid the most common pitfalls that harm the patient or cause embarrassment to the radiologist. To paraphrase Sleeping Beauty: “I cannot undo this fearful curse because Maleficent’s powers are too great; but I can ameliorate it!”
Educational aims:
• To identify 10 common causes of error in oncology image reporting
References:
• Minimising the impact of errors in the interpretation of CT images for surveillance and evaluation of therapy in cancer”. Clinical Radiology (2016): 71(11),1083-1094.

0.5 CPD credit
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.
 

Duration:19 mins


Speaker info

Bruno Morgan

Professor Bruno Morgan Professor of Cancer Imaging and Radiology, University Hospitals of Leicester and the University of Leicester Professor Bruno Morgan specialises in research, interventional and diagnostic cancer radiology at the University Hospitals Leicester. He is also helping to develop forensic radiology in the UK. His oncology research is mainly based around imaging applications to monitor drug therapy. Professor Morgan manages the use of imaging in research at University Hospitals of Leicester, providing reporting and regulatory oversight. He has carried out “independent reviews” of imaging for clinical trials, mainly reviewing response evaluation criteria in solid tumors (RECIST) derived end-points, for Cancer Research UK (CRUK), EORTC and pharmaceutical companies. He teaches all aspects of oncology imaging and particularly those related to clinical trials: to CRUK, pharmaceutical